Darin Lippoldt, Chief Legal Officer of Neurocrine Biosciences Inc., filed a Form 4 on September 15, 2026, disclosing the vesting of performance restricted stock units and a related tax withholding transaction dated September 11, 2026.

Key Highlights

  • PRSU vesting: 4,483 shares of common stock were acquired at $0 on September 11, 2026, following certification that a performance metric had been achieved.
  • Tax withholding: 2,419 shares were withheld by the company at $156.22 per share to satisfy tax withholding requirements on the PRSU vesting; no shares were sold.
  • Post-transaction ownership: Lippoldt directly holds 56,793 shares of common stock following the reported transactions.
  • Role: Darin Lippoldt is identified in the filing as Chief Legal Officer of Neurocrine Biosciences Inc. (NASDAQ:NBIX).
  • No derivative securities: No transactions in derivative securities were reported in Table II.

PRSU Certification and Share Withholding at Neurocrine Biosciences

According to the filing, Darin Lippoldt, Chief Legal Officer of Neurocrine Biosciences Inc. (NASDAQ:NBIX), reported two transactions in common stock, both dated September 11, 2026. The first transaction was an acquisition of 4,483 shares coded "A," reflecting the vesting of performance restricted stock units (PRSUs). The filing states that Lippoldt "was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026." The acquisition price for these shares was listed as $0.

The second transaction, coded "F," involved 2,419 shares disposed of at a price of $156.22 per share. The filing describes these as "shares withheld by Neurocrine Biosciences, Inc. (the 'Company' or 'Issuer') to satisfy tax withholding requirements on vesting of PRSUs," and explicitly notes that "no shares were sold." Following both transactions, Lippoldt's direct beneficial ownership of common stock stands at 56,793 shares, according to the filing.

The Form 4 was filed by one reporting person and is not marked as an amendment. No transactions in derivative securities were disclosed in Table II of the filing. The document was signed by Darin Lippoldt and dated September 15, 2026.

What Was Disclosed

The filing reports the vesting of PRSUs resulting in 4,483 shares acquired by Neurocrine Biosciences' Chief Legal Officer, and the withholding of 2,419 shares at $156.22 each for tax purposes, leaving the officer with direct ownership of 56,793 shares.